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Abstract 
 
Two of the most devastating neurodegenerative diseases are consequences out of 
misfolding and aggregation of key proteins-alpha synuclein and beta-amyloid. Although 
the primary targets for the two proteins are different, they both share a common 
mechanism that involves formation of pore-like structure on the plasma membrane, 
consequent dysregulation of calcium homeostasis, mitochondrial dysfunction and 
oxidative damage. The combined effect of all this factors ultimately leads to neuronal cell 
death. Whereas beta amyloid acts on the astrocytic plasma membrane, exhibiting a tight 
dependence to the membrane cholesterol content, alpha–synuclein does not distinguish 
between type of membrane or cell. Additionally, oligomeric forms of both proteins 
produce reactive oxygen species through different mechanisms: beta-amyloid through 
activation of the NADPH oxidase and alpha-synuclein through non-enzymatic way. 
Finally, both peptides in oligomeric form induce mitochondrial depolarisation through 
calcium overload and free radical production that ultimately lead to opening of the 
mitochondrial permeability transition pore and trigger cell death.  
 
 
 
 
 
INTRODUCTION 
 
Neurodegenerative diseases are devastating and currently incurable, and are increasing 
progressively in aging populations. Neurodegenerative disorders, from most common 
Alzheimer’s disease to prion disease are share a several common feature such an 
aggregation and deposition of misfolded proteins in the brain and involvement of calcium 
deregulation, energy disbalance and oxidative stress in pathogenesis. The most 
intensively studied misfolded proteins are beta-amyloid (main component of the 
extracellular senile plaques in Alzheimer’s disease) and alpha-synuclein (aggregates as 
intracellular Lewy bodies in Parkinson’s disease).  These deposits consist predominantly 
of protein fibrils and have long been thought to be the trigger of cellular dysregulations 
and reason for neuronal loss in these diseases but in last several years the number of 
studies proves that oligomeric forms of these proteins are more toxic than monomeric or 
fibril forms. 
The role of unfolded proteins in neurodegeneration is intensively debating for 
number of years. As one of the argument is induction of neuronal loss before appearance 
of aggregated peptides and also localisation of the aggregated proteins – intracellular (for 
tau and α-synuclein) and β-amyloid (extracellular) with no trafficking through membranes. 
However, more toxic forms - oligomers are membrane permeable, allowing the passing 
of plasma and intracellular membranes and therefore protein propagation throughout 
neurons and astrocytes in the brain [41];[66]. The propagation hypothesis in 
neurodegenerative disease has found support when oligomeric forms of α-synuclein and 
tau have been found in cerebrospinal fluid and in neuronal graft studies. It also important 
that familial forms of AD are caused by a mutation in one of 3 genes which regulates βA 
production: presenilin 1 (PS1), presenilin 2 (PS2) and amyloid precursor protein (APP), 
that also prove importance of the β-amyloid studies. The role of aggregated α-synuclein 
in PD is also proven in familial (mutation in gene coding α-synuclein) and sporadic form 
of disease [63].  
Calcium is the most pleiotropic ion and is able to trigger majority of intracellular 
pathways in all cell types in response to external or internal stimuli. In brain, and 
especially in neurons, Ca2+ plays a fundamental role in synaptic transmission, plasticity, 
transport, and neuron-neuron and neuron-glia signalling [22]. Any alterations of the 
physiological calcium signal in neurons or astrocytes lead to changes in signal 
transduction and cells death. Calcium dysregulation is shown to be one of the factors 
which trigger neurodegeneration in AD and PD [35;19].  
There are a number of hypotheses concerning the pathogenesis of 
neurodegeneration in AD and PD, and these include the misfolding of proteins or the 
involvement of other pathological processes such as neuroinflammation or vascular 
pathology. Despite these different hypotheses for the aetiology of neurodegeneration, the 
unifying and undisputed feature seen in sporadic AD and PD is the occurrence of 
oxidative stress [36; 39].  
Calcium signalling and enzymatic generation of reactive oxygen species are in 
close interaction and can stimulate each over in physiology [31;11;71]. The combined 
effect of oxidative stress and calcium deregulation is the trigger for cell death in the brain 
via multiple pathways [36;20]. Considering this, it is very important to shed more light on 
the nature of interplay between calcium signal and free radicals in the context of 
perturbation of physiological conditions, mitochondrial dysfunction and 
neurodegeneration upon application of oligomeric misfolded proteins. Here we review the 
changes in redox state and calcium signalling in pathological conditions under the 
influence of misfolded proteins involved in two most common neurodegenerative 
disorders AD and PD. 
 
Unfolded proteins and calcium signalling  
β-amyloid  
The possible role of the βA in pathological calcium signalling was discussed after 
finding the ability of βA 1-42 and 1-40 to form channels and pores in artificial 
membranes [14;15]. The effects of the βA on calcium signals were tested on the 
different cell types with broad variability of results [10]. One of the explanation of the 
diversity of the effects could be the fact that βA should be aggregated (oligomeric of 
fibril) for forming the pore in membranes and induce the calcium signal [28;29;43]. The 
effects of βA on the calcium signal are also cell specific. Thus, we have found that full 
peptides βA 1-42 and βA1-40 and different short forms βA 25-35, βA 25-40 or βA 1-28 in 
micromolar concentrations are able to induce [Ca2+]c changes in astrocytes, but not in neurons 
[3;4;5;42].  Cytosolic Ca2+ elevation in astrocytes was crucial for neuronal cell death under βA 
exposure [3;7]. Importantly, the specificity of the βA to the astrocytes was not linked to any 
receptors or ion channels activation but was induced by incorporation of βA into the membrane 
with pore formation. This selectivity of the astrocytes to βA induced calcium signal is explained 
by their higher content of cholesterol in their plasma membrane compare to neurons [8]. 
Manipulation of the membrane cholesterol content in co-culture of neurons and astrocytes 
changes their ability to induce the calcium signal in response to βA and increase of cholesterol 
content in neuronal membrane make these cells to be able generate calcium signal in response 
to βA, while decrease of cholesterol in membranes block βA-induced calcium signal and 
neurotoxicity [8]. Importance of cholesterol for incorporation of βA into membrane and pore 
formation is shown by number of studies [30;53] and βA-induced channels can be blocked by 
compound, which compete with cholesterol for binding with C–terminal of βA [34]. βA is able to 
form pores on the plasma membrane of astrocytes (but not in neurons) in very low 
concentrations and only 1 molecules of oligomeric βA 1-42 can stimulate Ca2+-influx to astrocyte 
[56]. 
α-synuclein 
Oligomeric α-synuclein is also able to form pore-like structures with non-selective leakage 
of compounds [73;61]. Monomers of α-synuclein have also been reported to affect membranes 
through differing mechanisms that is, altering permeability or inducing channel formation 
[72;74]. Interestingly, the effects of exogenous α-synuclein on the calcium signalling was in 
contrast to βA independent of cell type and it was able to induce elevation of cytosolic Ca2+ in 
both neurons and astrocytes from different brain regions [13]. Interestingly, monomeric α-
synuclein, which play physiological role in synaptic transduction [21], also induced calcium 
signal in neurons and astrocytes in concentrations, which is close to physiological [13]. Both – 
monomeric and oligomeric α-synucleins are induced calcium signal, but only oligomers induced 
neuronal cell death, which can be prevented by inhibition of this signal by calcium free medium 
[13]. It suggests the importance of the calcium signal in neurodegeneration induced by 
aggregated βA and α-synuclein but strongly suggests some other coherent players in the 
mechanism of the neurodegeneration. 
β-amyloid and α-synuclein induce ROS production via different mechanisms 
The role of oxidative stress is increasingly recognised in neurological and 
neurodegenerative disorders [36;39]. Oxidative stress is caused by an imbalance in the redox 
state of the cell, either by overproduction of reactive oxygen species (ROS), or by dysfunction of 
the endogenous antioxidant systems. Increased levels of malondialdehyde and 4-
hydroxynonenal (markers for oxidative stress – products of lipid peroxidation) were found in 
brain tissue and cerebrospinal fluid (SCF) of AD patients compared to controls [48]. This effect 
may be induced by βA, which able to accelerate lipid peroxidation in neurons and astrocytes 
[10]. 
Major antioxidant in the brain is glutathione (GSH). The level of GSH is the indicator of 
redox balance in the brain cells. We found that βA can induce profound decrease in glutathione 
of astrocytes. This effect could be averted in both neurons and astrocytes by inhibition of the 
astrocytic calcium signal using Ca2+-free medium [3;4;5]. It suggests that βA induced calcium 
dependent ROS production in astrocytes which consequently affects neurons [6].  
Oligomeric but not fibril or monomeric α-synuclein is able to induce oxidative stress that results 
in decreased level of GSH in neurons and astrocytes. Importantly triplication of α-synuclein also 
demonstrated reduction in glutathione in human neurons derived from iPS cells [26]. However, 
α-synuclein can directly activate glutathione peroxidase for prevention of oxidative stress [46].   
 
βA produced ROS from the various enzymatic sources [57]. For oligomeric and fibrillar βA was 
also suggested production of free radicals in the interaction with copper [27].  βА can activate 
NADPH oxidase through several  mechanisms, thus in neutrophils from Alzheimer’s disease 
patients it can be stimulated through activation of P2X receptors, in microglia – through 
activation of the scavenger receptors CD36 [25]. We have found that full peptides βA 1-42 and 
1-40 and also short peptides can activate astrocytic NADPH oxidase [4;6] after stimulation of 
calcium signal, more likely through the Ca2+-dependent activation of protein kinase C β [4;6]. 
Although expression of different forms of NADPH oxidase was also reported for neurons [18], 
βA did not activate ROS production in neurons, that can be explained by the absence of the βA 
– induced calcium signal [3;5]. Activation of NADPH oxidase in astrocytes is one of the key 
elements in the mechanism of βA-induced neurotoxicity – application of inhibitors of this 
enzyme is protective against neuronal and astrocytic cell death [4;6;16;40;58].  
It is of particular importance that the βA-induced calcium signal is a trigger for NADPH 
oxidase activation. For example, inhibitors of NADPH oxidase, melatonin or antibodies for 
acetylcholine receptors failed to alter [Ca2+]c in astrocytes but significantly reduced ROS 
production and protected both neurons and astrocytes against cell death  [4;6;36;42;44]. 
Importantly, increased expression of Nox2 and Nox4 is shown for Alzheimer’s brain and for cell 
cultures treated with βA.  
α-synuclein   
The ability of alpha-synuclein to produce ROS when externally added is directly dependent 
on its tertiary structure. In our hands only β-sheet-rich oligomers and to some extend fibrils of α-
synuclein were able to produce significant rise in ROS production and to reduce the endogenous 
GSH levels [26].  We have shown that in cells with α-synuclein triplication as well as in primary 
neurons and astrocytes the rate of superoxide production, hydrogen peroxide production or 
generally lipid peroxidation are immensely augmented following application of nanomolar 
concentration of beta-sheet type oligomeric α-synuclein aggregates [12;26]. 
It has been largely speculated that alpha-synuclein could produce ROS through activation 
of the NADPH oxidase similar to β-amyloid (36). However, inhibitors of the NADPH oxidase such 
as 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF) or dibenziodolium chloride (DPI), has been 
shown to be only partially protective against oligomeric α-synuclein-induced ROS [26]. These 
inhibitors are not highly specific to NADPH oxidase and influence the production of ROS by other 
cellular sources like NOS, XO or mitochondrial enzymes. Therefore the effect of α-synuclein on 
the activation of ROS production by NADPH oxidase is only secondary, most likely by increasing 
the permeability of the plasma membrane for calcium ions [13]. 
We demonstrated the increased of the basal ROS production rate in overexpression of α-
synuclein in human iPSC model. Moreover, picomolar concentrations of externally applied beta-
sheet form of α-synuclein oligomers produced excessive free radical productions that we found to 
be dependent on the presence of transition metals [26]. Thus, pre-treatment of the cells with 
metal chelators as desferrioxamine (DFO), clioquinol (CLQ), D-pencillamine (D-PEN), etc. to 
target iron, copper or zinc ions as potentially important in the ROS production be α-synuclein 
oligomers turned out to be largely protective [26].  
 
Effect of misfolded proteins on mitochondria 
β-amyloid 
 
Despite the number of publications about localisation of the βA in mitochondria [9;52], effect of 
oligomeric and fibrillar peptide on the function of this organelle is more likely to be via βA-induced 
signals such a NO production, ROS generation and calcium signal [1;10]. βA induced two types 
of mitochondrial depolarisation in astrocytes – one, fast and transient, is calcium dependent, 
second type is slow and progressive and is dependent on the superoxide production from 
NADPH oxidase [4]. Importantly, chemical or molecular (gp91 kd) inhibition of NADPH oxidase 
protected astrocytes and neurons by blocking both types of mitochondrial depolarisation [6]. 
NADPH oxidase and calcium activate phospholipase A which participates in βA-induced 
mitochondrial depolarisation [75]. Combination of free radicals production and calcium overload 
induce opening of mitochondrial permeability transition pore (mPTP), which was a reason for fast 
and transient mitochondrial depolarisation [4;6;2] and cytochrome C release [45]. The effect of βA 
to induce PTP opening was proven on isolated mitochondria [59;68;54] and live cells [4;7].   
Importantly, cyclophylin D knockout mice (model, which prevents or delay PTP opening) protects 
mitochondrial and neuronal disbalance and improve memory in Alzheimer’s disease mouse 
model [32;33]. βA-induced slow mitochondrial depolarisation, which induced by inhibition of 
mitochondrial respiration by lack of substrates [2;23]. This effect is initiated by production of 
superoxide in NADPH oxidase, which damages DNA and activates DNA repairing enzyme PARP. 
PARP consumes NAD and limits NADH pool for mitochondrial respiration [2;70]. The activation of 
PARP is shown for patient’s brain [24;47;60] Thus, βA-induced calcium signal activates free 
radicals production by NADPH oxidase, stimulates PARP activation and reduction of GSH that 
lead to mitochondrial deregulation, opening PTP and initiation of the cell death (Figure 1). 
α -synuclein 
Implication of mitochondria in pathology of Parkinson’ Disease shown for long time, first for 
toxic models (rotenone and MPTP+), complex I deficiency [65;69] and, more recently on familial 
form of this disease [20;37]. Oligomeric α-synuclein shown to be able to inhibit mitochondrial 
complex I [49;62] and induced mitochondrial depolarisation [17;67].  Importantly, cells with 
triplication of alpha-synuclein also demonstrated mitochondrial dysfunction [50;64]. The role of α-
synuclein in mitophagy, mitochondrial fission/fusion and protein trafficking to this organelle is also 
shown [38;55]. α-synuclein transgenic mice is thought to induce neurodegeneration via activation 
of mitochondrial permeability transition pore [51]. Activation of mPTP opening by oligomeric α-
synuclein seems more likely compared to monomeric peptide  due to ability to induce calcium 
signal [13] and produce ROS in combination with heavy metal ions [26]– Figure 2.  
 
Despite the high toxicity of βA and α-synuclein, the mechanisms of neurodegeneration 
induced by these peptides are very complex and could be prevented on different stages. One of 
the most important steps is oligomerisation of these peptides. Intercommunication of the cells, 
especially in βA toxicity, is also very important and neurodegeneration can be induced by 
activation of microglia or astrocytes [10]. Inside of the cells, activation of one process, such a 
calcium signal by oligomeric α-syn or βA activates enzymatic ROS production and combination of 
oxidative stress and calcium overload affect mitochondria which trigger the cell death cascade 
(Figure 1-2).     
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Figure Legends 
Figure 1. Interplay of calcium, oxidative stress and mitochondria in the mechanism of β-
amyloid-induced neuronal cell death 
Figure 2. The effect of α-synuclein on neurons. Both monomeric and oligomeric forms of α-
synuclein modify plasma membrane and induce Ca2+ signal. Monomeric α-synuclein is not toxic 
for neurons despite inhibition of active calcium transport in neurons. Oligomeric α-synuclein 
producing free radicals and in combination with high calcium induce cell death.    
